Spurstone Advisory Services’s Xeris Biopharma Holdings XERS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.85K Hold
200
– – 0.02% 62
2026
Q2
$1.6K Hold
200
– – 0.02% 63
2026
Q1
$1.16K Hold
200
– – 0.02% 48
2025
Q4
$1.57K Hold
200
– – 0.02% 65
2025
Q3
$1.63K Hold
200
– – 0.02% 81
2025
Q2
$934 Hold
200
– – 0.01% 110
2025
Q1
$1.1K Hold
200
– – 0.02% 73
2024
Q4
$678 Buy
+200
New +$643 0.01% 64

Other funds holding XERS

Spurstone Advisory Services's XERS Position: Q3 2026 in Review

Spurstone Advisory Services held its Xeris Biopharma Holdings (XERS) position steady in Q3 2026 at 200 shares worth $1.85K. The position accounts for 0.02% of the portfolio, ranked #62.

Spurstone Advisory Services first reported a position in XERS in Q4 2024 and has held it in 8 quarters since. 246 funds tracked by Wall St. Rank hold XERS as of Q3 2026.

  • Spurstone Advisory Services held 200 shares of Xeris Biopharma Holdings worth $1.85K as of Q3 2026.
  • Spurstone Advisory Services left its Xeris Biopharma Holdings share count unchanged in Q3 2026.
  • Xeris Biopharma Holdings made up 0.02% of Spurstone Advisory Services's portfolio in Q3 2026, its #62 holding.
  • Spurstone Advisory Services first reported a position in Xeris Biopharma Holdings in Q4 2024 and has held it in 8 quarters since.
  • 246 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2026.

Based on Spurstone Advisory Services's 13F filing for Q3 2026, filed 2 Nov 2026.